The coronavirus disease 2019 (COVID-19) is caused by the SARSCoV-2 virus. A critical step of infection is when the virus enters human host cells, which is enabled by the interaction between the SARS-CoV-2 Spike (S) protein's receptor binding domain (RBD) on the surface of the viral particle and the Angiotensin I Converting Enzyme 2 (ACE2) receptor on the surface of human cells. Thus, the identification of small molecules, antibodies, or other biological molecules that interfere with the formation of the S-ACE2 complex could help to develop drugs to prevent or treat COVID19.

COVID-19 Spike-ACE2 binding assay kit is a rapid, simple, and sensitive method to characterize the binding affinity of the SACE2 complex in the presence of potential inhibitors. The in vitro enzymelinked immunosorbent assay can measure numerous reagents and conditions simultaneously. For example, this kit can be used for screening inhibitor activity and drugs, vaccine development, and testing potential therapeutic antibodies.